Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials

Non-alcoholic steatohepatitis (NASH) results from inflammation and hepatocyte injury in the setting of hepatic steatosis. Non-alcoholic steatohepatitis increases the risk of progression to liver fibrosis and cirrhosis, and is the most rapidly growing etiology for liver failure and indication for liv...

Descripción completa

Detalles Bibliográficos
Autores principales: Connolly, James J., Ooka, Kohtaro, Lim, Joseph K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160309/
https://www.ncbi.nlm.nih.gov/pubmed/30271738
http://dx.doi.org/10.14218/JCTH.2017.00056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160309/
https://www.ncbi.nlm.nih.gov/pubmed/30271738
http://dx.doi.org/10.14218/JCTH.2017.00056

Ejemplares similares